TIDMEVOL 
 
RNS Number : 9150Q 
Evolve Capital PLC 
21 April 2009 
 

Evolve Capital Plc ("Evolve") 
 
 
Admission of Investee Company to Trading on PLUS-Quoted Market 
 
 
The directors of Evolve are pleased to announce that 3D Diagnostic Imaging Plc 
("3D" or the "Company"), a company in which Evolve has invested some GBP528,000 
as a part of a larger GBP2 million fundraising, has today been admitted to 
trading on the PLUS-quoted market with a market capitalisation of GBP6.855 
million. 
 
 
Following admission Evolve holds 40,639,286 shares in the Company, equivalent to 
41.5% of its issued share capital. 
 
 
The Company's wholly owned subsidiary, Cariescan Ltd, is based in Dundee and 
markets an innovative and highly accurate hand-held device for the early 
detection and monitoring of tooth decay (dental caries). 
 
 
Oliver Vaughan, Evolve's Chairman commented: 
 
 
"We are pleased with the successful outcome of the fundraising for the Company, 
which was project managed by Whim Gully Capital, and with its admission onto 
PLUS, which is a market that we are very supportive of. We are also pleased to 
have had the support of Scottish Enterprise who have invested GBP1 million into 
the Company." 
 
 
A copy of the Company's admission document is available on 
www.plusmarketsgroup.com and further information on the Company can be found at 
www.cariescan.com. 
 
 
 
 
Enquiries: 
 
 
Evolve Capital PLC 
Edward Vandyk    Tel: 020 7937 4445 
 
 
Fairfax I.S. PLC, Nominated Adviser 
Jeremy Porter    Tel: 020 7598 5368 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCUARURKURSUAR
Evolve Capital (LSE:EVOL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Evolve Capital Charts.
Evolve Capital (LSE:EVOL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Evolve Capital Charts.